Click chemistry platform is expected to improve the efficacy and safety of various anti-cancer therapies

On November 11, 2021, Shasqi announced the completion of a US$50 million Series B financing

Most cancer therapies usually only 1%-2% of the drug delivery can accurately target the tumor

▲The mechanism of the CAPAC technology platform (picture source: Shasqi's official website)

In preclinical models, this novel, highly targeted delivery technology can increase the active drug at the tumor site by more than 25 times, resulting in a high-level, sustainable response with fewer side effects than current methods

Shasqi's pilot project SQ3370, the interim data of the Phase 1 clinical trial for the treatment of advanced sarcoma and other solid tumors, was announced earlier this year, demonstrating the therapy’s encouraging safety profile and early signs of clinical activity

Reference materials:

[1] Shasqi Raises $50 Million to Expand Click Chemistry Platform Beyond Injectable Tumors and Accelerate Lead Clinical Program.

(The original text has been deleted)